Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | SHBG | P04278 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.67 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3868012 | 1.00 | ESR1 (0.67) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL11097284 | 1.00 | ESR1 (0.67) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL11874816 | 0.89 | ESR1 (0.68) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL5460095 | 0.89 | ESR1 (0.68) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL711024 | 0.89 | ESR1 (0.68) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL4749408 | 0.88 | ESR1 (0.67) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL10794417 | 0.88 | ESR1 (0.67) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL10794423 | 0.88 | ESR1 (0.67) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL10792759 | 0.87 | ESR1 (0.65) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL10792763 | 0.87 | ESR1 (0.65) | ESR1HSD17B10LMNAESR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008147640-A2 | HORMONE REPLACEMENT THERAPY | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-12-04 | — | — | WO | claimed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | claimed |
| EP-0044105-B1 | NEW 8-ALPHA-OESTRA-1,3,5(10)-TRIENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | AKZO N.V. (NL) | 1984-10-03 | — | — | EP | claimed |
| US-8110565-B2 | Of the ACE inhibitor ramipril; controlling the melting point by mixing with the free acid with the ramipril ethyl or methyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release | NOVEN PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8025898-B2 | Of the ACE inhibitor ramipril by mixing with the ramipril (m)ethyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release | NOVEN PHARMACEUTICALS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| WO-2011000116-A1 | USE OF STEROIDAL COMPOUNDS FOR THE CONVERSION OF NORMAL B LYMPHOCYTES INTO IMMUNOGLOBULIN-SECRETING PLASMA CELLS | Héma-Québec (CA) | 2011-01-06 | — | — | WO | disclosed |
| WO-2008147640-A2 | HORMONE REPLACEMENT THERAPY | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080167280-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167365-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20070275935-A1 | Estratriene Derivatives | CRYPTOPHARMA PTY LTD (AU) | 2007-11-29 | — | — | US | disclosed |
| CN-100345862-C | Steroid compounds preparation method | ZHEJIANG MEDICINE CO LTD (CN) | 2007-10-31 | — | — | CN | disclosed |
| CN-1867577-A | Estratriene derivatives | CRYPTOPHARMA PTY LTD (AU) | 2006-11-22 | — | — | CN | disclosed |
| EP-1625143-A1 | ESTRATRIENE DERIVATIVES | Cryptopharma Pty Ltd (AU) | 2006-02-15 | — | — | EP | disclosed |
| CN-1666993-A | Steroid compounds preparation method | ZHEJIANG MEDICINE CO LTD (CN) | 2005-09-14 | — | — | CN | disclosed |
| WO-2004101595-A1 | ESTRATRIENE DERIVATIVES | CRYPTOPHARMA PTY LTD (AU) | 2004-11-25 | — | — | WO | disclosed |
| EP-0044105-B1 | NEW 8-ALPHA-OESTRA-1,3,5(10)-TRIENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | AKZO N.V. (NL) | 1984-10-03 | — | — | EP | disclosed |
| US-3939186-A | Process for producing ethers of steroids | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293683-A1 | Hormone Replacement Therapy | ESR2, SHBG, ESRRG | ESR1 4/4885HSD17B10 215/4885LMNA 4487/4885 |
| US-20070275935-A1 | Estratriene Derivatives | ESR2, ESRRB, NR3C2 | ESR1 5/4885HSD17B10 219/4885LMNA 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.